MarketLens

Is Viking Therapeutics Poised to Disrupt the Weight-Loss Market

4 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Is GreenStream Water Poised to Disrupt the Global Desalination Market

3 months ago

The $100 Billion Weight Loss Revolution That's Reshaping Your Portfolio

10 months ago

From Value Meals to Weight-Loss Drugs: Navigating the Evolving Consumer Landscape

6 months ago

Is Nexus International Poised to Disrupt the Gaming Industry

5 months ago

Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished

Viking Therapeutics shares declined in July as investors weighed phase 3 trial costs over benefits, though long-term prospects remain intact. The pullback reflects near-term expense concerns rather th...

VKTX

Stock News•4 weeks ago

Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

Viking Therapeutics (VKTX) is highlighted by optimistic Wall Street analyst ratings, which often influence stock prices. The piece questions the real importance of these brokerage-firm recommendations...

VKTX

Stock News•1 months ago

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1

Viking Therapeutics started testing a next-gen weight loss drug that targets mechanisms beyond GLP-1, entering a field where Novo Nordisk and Eli Lilly already have advanced programs.

GLP

Stock News•1 months ago

Inside THNR: A Leaner Approach to Weight Loss Investing

THNR ETF offers exposure to the GLP-1 weight loss drug market, which has reshaped healthcare. Demand for these drugs continues to grow, providing a diversified investment vehicle.

THNR